Austedo XR (Deutetrabenazine) Patent Expiration, LOE Window & CMS Spending
Austedo XR (Deutetrabenazine) by Teva Pharmaceuticals: FDA Orange Book core substance LOE 2034-03-18 (last listed 2041-06-10), 0 AB generics, $750.0M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Teva Pharmaceuticals |
| FDA Application & Pathway | N216354 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2034-03-18 |
| Last Listed Patent or Exclusivity Date | 2041-06-10 |
| Orange Book Patents (*PED Extensions) | 23 patents (10 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $750.0M |
| 2024 Medicare Part D Spend | $597.2M |
| 2024 Medicaid Spend | $152.9M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Teva Pharmaceuticals across sibling Meru public-data platforms.